Press Releases

Filter per year
July 17, 2024
Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A
July 3, 2024
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
June 28, 2024
Media Update: Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS
June 26, 2024
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
June 25, 2024
Media Update: Riliprubart one-year results from phase 2 study underpin the potential as a first-in-class treatment in chronic inflammatory demyelinating polyneuropathy
June 25, 2024
Press Release: Availability of the Q2 2024 Aide-mémoire
June 21, 2024
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee
June 21, 2024
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
June 20, 2024
Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
June 3, 2024
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
June 1, 2024
Media Update: Sanofi update on Zantac litigation
May 31, 2024
Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
May 31, 2024
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
May 31, 2024
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
May 30, 2024
Press Release: Sanofi completes acquisition of Inhibrx, Inc.
May 27, 2024
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma
May 22, 2024
Media Update: New results from rilzabrutinib phase 2 study show potential to be first advanced oral treatment for moderate-to-severe asthma
May 21, 2024
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
May 20, 2024
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
May 13, 2024
Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty

Press Statements